Security key
92731L304
Vincerx Pharma, Inc. - Common Stock, $0.0001 par value per share (VINC)
CUSIP: 92731L304
Q2 2025 13F Holders as of 30 Jun 2025
- Type / Class
- Equity / Common Stock, $0.0001 par value per share
- Shares outstanding
- 44,796,006
- Total 13F shares
- 50
- Share change
- -220,575
- Total reported value
- $2
- Price per share
- $0.04
- Number of holders
- 1
- Value change
- -$116,793
- Number of buys
- 1
- Number of sells
- 13
Report period
Q2 2025
Institutions
1
Top holders
1
VINC full security history
Newer quarter: Q3 2025
Previous quarter: Q1 2025
Vincerx Pharma, Inc. SEC filings
Vincerx Pharma, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 92731L304
Recent filing periods:
Top shareholders of VINC - Vincerx Pharma, Inc. - Common Stock, $0.0001 par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC |
13D/G
|
— |
5%
|
274,908
|
$19,244 | -$294,015 | 31 Mar 2025 | |
| Prosight Management, LP |
13D/G
|
— |
5%
|
111,755
|
$7,823 | $0 | 31 Dec 2024 | |
| SAGE RHINO CAPITAL LLC |
13F
13D/G
|
Company |
0.19%
|
85,170
|
$45,089 | — | 31 Mar 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.1%
|
42,777
|
$22,646 | — | 31 Mar 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.07%
|
31,567
|
$16,712 | — | 31 Mar 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.04%
|
19,285
|
$10,211 | — | 31 Mar 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
0.03%
|
14,317
|
$7,574 | — | 31 Mar 2025 | |
| TWO SIGMA SECURITIES, LLC |
13F
|
Company |
0.02%
|
11,053
|
$5,851 | — | 31 Mar 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.02%
|
10,798
|
$5,716 | — | 31 Mar 2025 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0.01%
|
2,997
|
$1,587 | — | 31 Mar 2025 | |
| BlackRock, Inc. |
13F
|
Company |
0.01%
|
2,352
|
$1,246 | — | 31 Mar 2025 | |
| UBS Group AG |
13F
|
Company |
0%
|
142
|
$75 | — | 31 Mar 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0%
|
102
|
$54 | — | 31 Mar 2025 | |
| SBI Securities Co., Ltd. |
13F
|
Company |
0%
|
50
|
$26 | — | 31 Mar 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0%
|
15
|
$8 | — | 31 Mar 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0%
|
1
|
$1 | — | 31 Mar 2025 | |
| Rubric Capital Management LP |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
2,107,000
|
— | — | 20 Jan 2022 | |
| Andrew I. McDonald |
3/4/5
|
Director, 10%+ Owner |
—
class O/S missing
|
15,000
|
— | — | 26 May 2022 | |
| Christopher P. Lowe |
3/4/5
|
Director |
—
class O/S missing
|
40,000
|
$37,972 | — | 24 Aug 2022 | |
| Alexander A. Seelenberger |
3/4/5
|
Chief Financial Officer |
—
mixed-class rows
|
155,280
mixed-class rows
|
$28,745 | — | 12 Aug 2024 | |
| Ahmed Hamdy MD |
3/4/5
|
Chief Executive Officer, Director |
—
class O/S missing
|
200,000
|
— | — | 12 Aug 2024 | |
| Raquel E. Izumi |
3/4/5
|
President and Chief Operations Officer, Director |
—
class O/S missing
|
165,000
|
— | — | 12 Aug 2024 | |
| Tom C. Thomas |
3/4/5
|
General Counsel and Chief Legal Officer |
—
class O/S missing
|
125,000
|
— | — | 12 Aug 2024 | |
| Hermes de Jesus Garban |
3/4/5
|
Chief Medical Officer |
—
class O/S missing
|
55,250
|
— | — | 14 Feb 2022 | |
| Kevin Haas |
3/4/5
|
Acting Chief Financial Officer |
—
class O/S missing
|
42,776
|
— | — | 20 Dec 2024 | |
| Sooin Hwang |
3/4/5
|
Chief Business Officer |
—
class O/S missing
|
34,000
|
— | — | 14 Feb 2022 | |
| Xiaoming Zhang |
3/4/5
|
Chief Technology Officer |
—
class O/S missing
|
34,000
|
— | — | 14 Feb 2022 | |
| Brian J. Druker |
3/4/5
|
Director |
—
class O/S missing
|
15,000
|
— | — | 23 May 2024 | |
| Francisco D. Salva |
3/4/5
|
Director |
—
class O/S missing
|
15,000
|
— | — | 23 May 2024 | |
| John H. Lee |
3/4/5
|
Director |
—
class O/S missing
|
15,000
|
— | — | 23 May 2024 | |
| Laura I. Bushnell |
3/4/5
|
Director |
—
class O/S missing
|
15,000
|
— | — | 23 May 2024 | |
| Ruth E. Stevens |
3/4/5
|
Director |
—
class O/S missing
|
15,000
|
— | — | 23 May 2024 |
Institutional Holders of Vincerx Pharma, Inc. - Common Stock, $0.0001 par value per share (VINC) as of Q2 2025
As of 30 Jun 2025,
Vincerx Pharma, Inc. - Common Stock, $0.0001 par value per share (VINC) was held by
1 institutional
shareholder
that filed Form 13F with the SEC.
Together, they reported ownership of
50 shares.
The largest 1 holders included
Bank & Trust Co.
This page lists
1
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
13
Q2 2025 holders
1
Holder diff
-12
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 Value $ | Q2 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.